This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Warsame R, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, et al. Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. Am J Hematol. 2017;92:435–40.
Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541–9.
Lakshman A, Abeykoon JP, Kumar SK, Rajkumar SV, Dingli D, Buadi FK, et al. Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. Am J Hematol. 2017;92:1146–55.
Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319–31.
Kaufman GP, Schrier SL, Lafayette RA, Arai S, Witteles RM, Liedtke M. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood. 2017;130:900–2.
Khouri J, Bicky T, Reu FJ, Samaras CJ, Liu HD, Karam MA, et al. Daratumumab is safe and highly effective in AL amyloidosis. Blood. 2017;130(Suppl 1):1819–1819.
Kimmich C, Schönland S, Ziehl R, Ho AD, Dittrich T, Müller-Tidow C, et al. Daratumumab monotherapy in thirty-two heavily pre-treated patients with advanced systemic light-chain amyloidosis. Blood. 2017;130(Suppl 1):1837–1837.
Roussel M, Stoppa A-M, Perrot A, Karlin L, Arnulf B, Macro M, et al. A prospective phase II of daratumumab in previously-treated systemic light-chain (AL) amyloidosis. Blood. 2017;130(Suppl 1):508–508.
Sanchorawala V, Sarosiek S, Sloan JM, Brauneis D, Migre ME, Mistark M, et al. Safety and tolerability of daratumumab in patients with relapsed light chain (AL) amyloidosis: preliminary results of a phase II study. Blood. 2017;130(Suppl 1):507–507.
Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26:2317–25.
Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, et al. Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. Leukemia. 2018;32:729–35.
Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121:3420–7.
Mahmood S, Palladini G, Sanchorawala V, Wechalekar A. Update on treatment of light chain amyloidosis. Haematologica. 2014;99:209–21.
Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007;109:492–6.
Palladini G, Milani P, Foli A, Basset M, Russo F, Perlini S, et al. A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. Blood. 2017;129:2120–3.
Acknowledgements
We acknowledge all the patients, their families and the clinicians who were involved in the patients’ care. This research work has received ASCO 2018 Merit Award.
Author contributions
JPA, SZ and PK designed the study. JPA, SZ and PK collected analyzed and interpreted the data and wrote the first draft of the manuscript. AD, MAG, NL, TK, WG, EM, DD, MQL, SRH, FB, RW, RAK, VR and SK interpreted the data, critically revised the manuscript and all authors approved the final version.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Dr. Gertz has received funding from Amgen, Prothena, Annexon, Appellis, Johnson and Johnson and Celgene. Dr. Dispenzieri has received research funding from Jannsen, Takeda, Celgene, Pfizer, Alnylam, Prothena, and GSK and serves on the advisory board for Takeda and Intellia. Dr. Kumar received research grants for clinical trials from Celgene, Takeda, Janssen, BMS, Sanofi, KITE, Merck, Abbvie, Medimmune, Novartis, Roche-Genentech, Amgen. Dr. Leung serves on the advisory board for Takeda and Prothena. Dr. Kapoor is principal investigator on studies for which Mayo Clinic receives funding from Takeda, Sanofi, and Amgen. The remaining authors declare no conflicts of interest.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Abeykoon, J.P., Zanwar, S., Dispenzieri, A. et al. Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. Leukemia 33, 531–536 (2019). https://doi.org/10.1038/s41375-018-0262-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-018-0262-2
This article is cited by
-
Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA
Annals of Hematology (2023)
-
Efficacy and safety of intravenous daratumumab-based treatments for AL amyloidosis: a systematic review and meta-analysis
Cancer Cell International (2022)
-
Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation
Blood Cancer Journal (2022)
-
Immunotherapy in AL Amyloidosis
Current Treatment Options in Oncology (2022)
-
Targeted treatments of AL and ATTR amyloidosis
Heart Failure Reviews (2022)